{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:48:06Z","timestamp":1791920886557,"version":"4.3.4"},"reference-count":187,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,8,13]],"date-time":"2023-08-13T00:00:00Z","timestamp":1691884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Antiretroviral therapies (ARTs) have revolutionized the management of human immunodeficiency virus (HIV) infection, significantly improved patient outcomes, and reduced the mortality rate and incidence of acquired immunodeficiency syndrome (AIDS). However, despite the remarkable efficacy of ART, virologic failure remains a challenge in the long-term management of HIV-infected individuals. Virologic failure refers to the persistent detectable viral load in patients receiving ART, indicating an incomplete suppression of HIV replication. It can occur due to various factors, including poor medication adherence, drug resistance, suboptimal drug concentrations, drug interactions, and viral factors such as the emergence of drug-resistant strains. In recent years, extensive efforts have been made to understand and address virologic failure in order to optimize treatment outcomes. Strategies to prevent and manage virologic failure include improving treatment adherence through patient education, counselling, and supportive interventions. In addition, the regular monitoring of viral load and resistance testing enables the early detection of treatment failure and facilitates timely adjustments in ART regimens. Thus, the development of novel antiretroviral agents with improved potency, tolerability, and resistance profiles offers new options for patients experiencing virologic failure. However, new treatment options would also face virologic failure if not managed appropriately. A solution to virologic failure requires a comprehensive approach that combines individualized patient care, robust monitoring, and access to a range of antiretroviral drugs.<\/jats:p>","DOI":"10.3390\/v15081732","type":"journal-article","created":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T10:20:14Z","timestamp":1692008414000},"page":"1732","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":81,"title":["Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Frank Eric Tatsing","family":"Foka","sequence":"first","affiliation":[{"name":"Department of Microbiology, Virology Laboratory, School of Biological Sciences, Faculty of Natural and Agricultural Sciences, North West University, Mafikeng, Private Bag, Mmabatho X2046, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1551-3314","authenticated-orcid":false,"given":"Hazel Tumelo","family":"Mufhandu","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Virology Laboratory, School of Biological Sciences, Faculty of Natural and Agricultural Sciences, North West University, Mafikeng, Private Bag, Mmabatho X2046, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,13]]},"reference":[{"key":"ref_1","unstructured":"(2018). Spending on Health and HIV\/AIDS: Domestic Health Spending and Development Assistance in 188 Countries, 1995\u20132015. Lancet Lond. Engl., 391, 1799\u20131829."},{"key":"ref_2","unstructured":"(2023, May 04). The Joint United Nations Programme on HIV\/AIDS (UNAIDS). Available online: https:\/\/www.unaids.org\/en\/resources\/documents\/2023\/2022_unaids_data."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/COH.0000000000000583","article-title":"Fast-Track Cities: Striving to End Urban HIV Epidemics by 2030","volume":"14","author":"Duncombe","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_4","unstructured":"(2019). Global, Regional, and National Incidence, Prevalence, and Mortality of HIV, 1980\u20132017, and Forecasts to 2030, for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV, 6, e831\u2013e859."},{"key":"ref_5","unstructured":"Kemnic, T.R., and Gulick, P.G. (2022, April 06). HIV Antiretroviral Therapy, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK513308\/."},{"key":"ref_6","unstructured":"Cowan, E.A., McGowan, J.P., Fine, S.M., Vail, R.M., Merrick, S.T., Radix, A.E., Hoffmann, C.J., and Gonzalez, C.J. (2021). Diagnosis and Management of Acute HIV, Johns Hopkins University."},{"key":"ref_7","unstructured":"World Health Organization (WHO) (2016). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, WHO. [2nd ed.]. Available online: https:\/\/apps.who.int\/iris\/handle\/10665\/208825."},{"key":"ref_8","unstructured":"(2023, May 05). NIH\u2019s Office of AIDS Research, Available online: https:\/\/clinicalinfo.hiv.gov\/en\/glossary\/virologic-failure."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of Virologic Failure and HIV Drug Resistance","volume":"33","author":"McCluskey","year":"2019","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106343","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 Integrase Strand Transfer Inhibitors: A Review of Current Drugs, Recent Advances and Drug Resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Healthcare Interventions: Explanation and Elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5714035","DOI":"10.1155\/2022\/5714035","article-title":"Potential of Azadirachta Indica as a Capping Agent for Antiviral Nanoparticles against SARS-CoV-2","volume":"2022","author":"Foka","year":"2022","journal-title":"BioMed Res. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1126\/science.235.4796.1570-b","article-title":"FDA Approves AZT","volume":"235","author":"Kolata","year":"1987","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm0703-839","article-title":"HIV and AIDS: 20 Years of Science","volume":"9","author":"Fauci","year":"2003","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","article-title":"Update and Latest Advances in Antiretroviral Therapy","volume":"43","author":"Delgado","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV Drugs: 25 Compounds Approved within 25 Years after the Discovery of HIV","volume":"33","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lee, F.J., Amin, J., and Carr, A. (2014). Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks\u2019 Follow-Up. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097482"},{"key":"ref_18","unstructured":"Patel, P.H., and Zulfiqar, H. (2023, March 11). Reverse Transcriptase Inhibitors, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551504."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1128\/jvi.68.3.1660-1666.1994","article-title":"Nevirapine Resistance Mutations of Human Immunodeficiency Virus Type 1 Selected during Therapy","volume":"68","author":"Richman","year":"1994","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/aid.2016.0133","article-title":"Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India","volume":"33","author":"Saravanan","year":"2017","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1089\/aid.2017.0135","article-title":"Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana","volume":"34","author":"Diphoko","year":"2018","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_22","unstructured":"(2023, March 11). Stanford University HIV Drug Resistance Database. Available online: https:\/\/hivdb.stanford.edu\/dr-summary\/resistance-notes\/NNRTI\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QAI.0000000000001723","article-title":"Raltegravir 1200 Mg Once Daily vs 400 Mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial","volume":"78","author":"Cahn","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11908-012-0305-1","article-title":"HIV Drug Resistance and the Advent of Integrase Inhibitors","volume":"15","author":"Quashie","year":"2013","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_25","first-page":"95","article-title":"HIV Protease Inhibitors: A Review of Molecular Selectivity and Toxicity","volume":"7","author":"Lv","year":"2015","journal-title":"HIV\/AIDS Res. Palliat. Care"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1089\/aid.2010.0057","article-title":"Evaluation of Primary Resistance to HIV Entry Inhibitors among Brazilian Patients Failing Reverse Transcriptase\/Protease Inhibitors Treatment Reveal High Prevalence of Maraviroc Resistance-Related Mutations","volume":"26","author":"Alencar","year":"2010","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12977-022-00608-1","article-title":"A Clinical Review of HIV Integrase Strand Transfer Inhibitors (INSTIs) for the Prevention and Treatment of HIV-1 Infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E\/C\/F) for Initial HIV-1 Treatment: Week 144 Results","volume":"75","author":"Arribas","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor in Vitro","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e00922-17","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations Located Outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors","volume":"8","author":"Malet","year":"2017","journal-title":"mBio"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev-med-052010-145454","article-title":"CCR5 Antagonism in HIV Infection: Current Concepts and Future Opportunities","volume":"63","author":"Wilkin","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2146\/ajhp080206","article-title":"Maraviroc: A Coreceptor CCR5 Antagonist for Management of HIV Infection","volume":"66","author":"Yost","year":"2009","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_33","first-page":"5447","article-title":"Maraviroc: A Review of Its Use in HIV Infection and Beyond","volume":"9","author":"Woollard","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1056\/NEJMoa0803154","article-title":"Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection","volume":"359","author":"Nelson","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1128\/AAC.01534-13","article-title":"Genotypic Analysis of the V3 Region of HIV from Virologic Nonresponders to Maraviroc-Containing Regimens Reveals Distinct Patterns of Failure","volume":"57","author":"Swenson","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Xiao, T., Cai, Y., and Chen, B. (2021). HIV-1 Entry and Membrane Fusion Inhibitors. Viruses, 13.","DOI":"10.3390\/v13050735"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8724549","DOI":"10.1155\/2018\/8724549","article-title":"Antibody-Mediated Therapy against HIV\/AIDS: Where Are We Standing Now?","volume":"2018","author":"Awi","year":"2018","journal-title":"J. Pathog."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e25829","DOI":"10.1002\/jia2.25829","article-title":"Broadly Neutralizing Monoclonal Antibodies for HIV Prevention","volume":"24","author":"Miner","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/aid.2011.0226","article-title":"Monoclonal Antibody-Based Candidate Therapeutics against HIV Type 1","volume":"28","author":"Chen","year":"2012","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_40","first-page":"411","article-title":"Nucleotide Reverse Transcriptase Inhibitors: A Thorough Review, Present Status and Future Perspective as HIV Therapeutics","volume":"15","author":"Holec","year":"2017","journal-title":"Curr. HIV Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.48.4.1089-1095.2004","article-title":"Role of Purine Nucleoside Phosphorylase in Interactions between 2\u2032,3\u2032-Dideoxyinosine and Allopurinol, Ganciclovir, or Tenofovir","volume":"48","author":"Ray","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1208\/s12248-012-9404-z","article-title":"Regulatory Pathways for ATP-Binding Cassette Transport Proteins in Kidney Proximal Tubules","volume":"14","author":"Masereeuw","year":"2012","journal-title":"AAPS J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1124\/mol.63.1.65","article-title":"Breast Cancer Resistance Protein (BCRP\/ABCG2) Induces Cellular Resistance to HIV-1 Nucleoside Reverse Transcriptase Inhibitors","volume":"63","author":"Wang","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1468-1293.2009.00716.x","article-title":"Tenofovir-Associated Renal and Bone Toxicity","volume":"10","author":"Woodward","year":"2009","journal-title":"HIV Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/em.20223","article-title":"A Brief Overview of Mechanisms of Mitochondrial Toxicity from NRTIs","volume":"48","author":"Kohler","year":"2007","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1258\/095646205774988127","article-title":"Skeletal Myopathy Associated with Nucleoside Reverse Transcriptase Inhibitor Therapy: Potential Benefit of Coenzyme Q10 Therapy","volume":"16","author":"Rosenfeldt","year":"2005","journal-title":"Int. J. STD AIDS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clnu.2004.03.009","article-title":"Hyperlactataemia and Lactic Acidosis in HIV-Infected Patients Receiving Antiretroviral Therapy","volume":"24","author":"Calza","year":"2005","journal-title":"Clin. Nutr. Edinb. Scotl."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/875512251102700603","article-title":"Osteoporosis and Vitamin D Deficiency in HIV-Positive Patients","volume":"27","author":"Soffler","year":"2011","journal-title":"J. Pharm. Technol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/AAC.00005-16","article-title":"Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment","volume":"60","author":"Custodio","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1124\/dmd.108.020974","article-title":"Investigation of the Role of Breast Cancer Resistance Protein (Bcrp\/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse","volume":"36","author":"Giri","year":"2008","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 Antiretroviral Drug Therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3851\/IMP1607","article-title":"Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors","volume":"20","author":"Regina","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virusres.2008.01.002","article-title":"Mechanisms of Inhibition of HIV Replication by Non-Nucleoside Reverse Transcriptase Inhibitors","volume":"134","author":"Tachedjian","year":"2008","journal-title":"Virus Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non-Nucleoside Reverse Transcriptase Inhibitors: A Review on Pharmacokinetics, Pharmacodynamics, Safety and Tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J. Int. AIDS Soc."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Clarke, W., and Dasgupta, A. (2016). Clinical Challenges in Therapeutic Drug Monitoring, Elsevier.","DOI":"10.1016\/B978-0-12-802025-8.00001-5"},{"key":"ref_56","first-page":"1488","article-title":"Characterization of the in Vitro Biotransformation of the HIV-1 Reverse Transcriptase Inhibitor Nevirapine by Human Hepatic Cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/00912700122009728","article-title":"Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors","volume":"41","author":"Greenblatt","year":"2001","journal-title":"J. Clin. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1517\/14656566.2.12.2065","article-title":"The Role of Nevirapine in the Treatment of HIV-1 Disease","volume":"2","author":"Podzamczer","year":"2001","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1517\/17425255.4.7.965","article-title":"Efavirenz--Still First-Line King?","volume":"4","author":"Best","year":"2008","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/589297","article-title":"Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel","volume":"47","author":"Hirsch","year":"2008","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nastri, B.M., Pagliano, P., Zannella, C., Folliero, V., Masullo, A., Rinaldi, L., Galdiero, M., and Franci, G. (2023). HIV and Drug-Resistant Subtypes. Microorganisms, 11.","DOI":"10.3390\/microorganisms11010221"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00002018-199920020-00005","article-title":"Drug Interactions of HIV Protease Inhibitors","volume":"20","author":"Malaty","year":"1999","journal-title":"Drug Saf."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/COH.0b013e3283139134","article-title":"HIV Protease Inhibitors and Insulin Resistance: Lessons from in-Vitro, Rodent and Healthy Human Volunteer Models","volume":"3","author":"Hruz","year":"2008","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJMoa022048","article-title":"Cardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infection","volume":"348","author":"Bozzette","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/QAD.0000000000000262","article-title":"HIV Protease Inhibitor Exposure Predicts Cerebral Small Vessel Disease","volume":"28","author":"Soontornniyomkij","year":"2014","journal-title":"AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/aid.2021.0227","article-title":"Molecular Characterization of the Pol Gene of Vertically Transmitted HIV-1 Strains in Children with Virological Failure","volume":"38","author":"Karunaianantham","year":"2022","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_67","first-page":"481314","article-title":"HIV-1 Genetic Variability and Clinical Implications","volume":"2013","author":"Santoro","year":"2013","journal-title":"Int. Sch. Res. Not."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fmicb.2020.00438","article-title":"Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa","volume":"11","author":"Obasa","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-020-00898-8","article-title":"Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review","volume":"59","author":"Podany","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Berghuis, A., Matlashewski, G., Wainberg, M.A., Sheppard, D., and Gotte, M. (2017). Handbook of Antimicrobial Resistance, Springer.","DOI":"10.1007\/978-1-4939-0694-9"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1128\/AAC.00204-13","article-title":"Multiple Genetic Pathways Involving Amino Acid Position 143 of HIV-1 Integrase Are Preferentially Associated with Specific Secondary Amino Acid Substitutions and Confer Resistance to Raltegravir and Cross-Resistance to Elvitegravir","volume":"57","author":"Huang","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1021\/jm5001908","article-title":"4-Amino-1-Hydroxy-2-Oxo-1,8-Naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1","volume":"57","author":"Zhao","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.1097\/QAI.0000000000000057","article-title":"A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir DF versus Single-Tablet Regimen Efavirenz\/Emtricitabine\/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results","volume":"65","author":"Wohl","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"a006866","DOI":"10.1101\/cshperspect.a006866","article-title":"HIV: Cell Binding and Entry","volume":"2","author":"Wilen","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.272.5270.1955","article-title":"CC CKR5: A RANTES, MIP-1alpha, MIP-1beta Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1","volume":"272","author":"Alkhatib","year":"1996","journal-title":"Science"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/AAC.00821-07","article-title":"Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)","volume":"52","author":"Nichols","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/QAI.0b013e3181e2cba0","article-title":"Three-Year Safety and Efficacy of Vicriviroc, a CCR5 Antagonist, in HIV-1-Infected Treatment-Experienced Patients","volume":"54","author":"Wilkin","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Anstee, Q.M., Neuschwander-Tetri, B.A., Wai-Sun Wong, V., Abdelmalek, M.F., Rodriguez-Araujo, G., Landgren, H., Park, G.S., Bedossa, P., Alkhouri, N., and Tacke, F. (2023). Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc., online ahead of print.","DOI":"10.1016\/j.cgh.2023.04.003"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2125.2008.03137.x","article-title":"Assessment of the Absorption, Metabolism and Absolute Bioavailability of Maraviroc in Healthy Male Subjects","volume":"65","author":"Abel","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3390\/v5020595","article-title":"HIV-1 Diversity in the Envelope Glycoproteins: Implications for Viral Entry Inhibition","volume":"5","author":"Almeida","year":"2013","journal-title":"Viruses"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcv.2012.01.005","article-title":"Naturally Occurring Resistance Mutations to HIV-1 Entry Inhibitors in Subtypes B, C, and CRF31_BC","volume":"54","author":"Junqueira","year":"2012","journal-title":"J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1074\/jbc.RA119.007360","article-title":"HIV-1 Anchor Inhibitors and Membrane Fusion Inhibitors Target Distinct but Overlapping Steps in Virus Entry","volume":"294","author":"Eggink","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1089\/aid.2009.0181","article-title":"Short Communication: Antiretroviral Therapy Resistance Mutations Present in the HIV Type 1 Subtype C Pol and Env Regions from Therapy-Naive Patients in Zambia","volume":"26","author":"Gonzalez","year":"2010","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.str.2010.09.017","article-title":"Crystal Structure of HIV-1 Primary Receptor CD4 in Complex with a Potent Antiviral Antibody","volume":"18","author":"Freeman","year":"2010","journal-title":"Structure"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.str.2013.04.015","article-title":"Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Miniproteins Revealed by 1.5 \u00c5 Cocrystal Structure of Gp120 and M48U1","volume":"21","author":"Acharya","year":"2013","journal-title":"Structure"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.bbamem.2013.12.022","article-title":"ADS-J1 Inhibits HIV-1 Infection and Membrane Fusion by Targeting the Highly Conserved Pocket in the Gp41 NHR-Trimer","volume":"1838","author":"Yu","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13938","DOI":"10.1073\/pnas.0601036103","article-title":"Small Molecules That Bind the Inner Core of Gp41 and Inhibit HIV Envelope-Mediated Fusion","volume":"103","author":"Frey","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7843","DOI":"10.1021\/jm800869t","article-title":"Design, Synthesis, and Biological Evaluation of N-Carboxyphenylpyrrole Derivatives as Potent HIV Fusion Inhibitors Targeting Gp41","volume":"51","author":"Liu","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1073\/pnas.0908713106","article-title":"Role of HIV Membrane in Neutralization by Two Broadly Neutralizing Antibodies","volume":"106","author":"Alam","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1128\/JVI.02664-13","article-title":"Mechanism of HIV-1 Neutralization by Antibodies Targeting a Membrane-Proximal Region of Gp41","volume":"88","author":"Chen","year":"2014","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tim.2015.07.005","article-title":"Antiviral Monoclonal Antibodies: Can They Be More Than Simple Neutralizing Agents?","volume":"23","author":"Pelegrin","year":"2015","journal-title":"Trends Microbiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature23010","article-title":"Open and Closed Structures Reveal Allostery and Pliability in the HIV-1 Envelope Spike","volume":"547","author":"Ozorowski","year":"2017","journal-title":"Nature"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/nchembio.2460","article-title":"Crystal Structures of Trimeric HIV Envelope with Entry Inhibitors BMS-378806 and BMS-626529","volume":"13","author":"Pancera","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMra022812","article-title":"Novel Therapies Based on Mechanisms of HIV-1 Cell Entry","volume":"348","author":"Kilby","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.antiviral.2011.09.010","article-title":"The Efficacy of an Anti-CD4 Monoclonal Antibody for HIV-1 Treatment","volume":"92","author":"Fessel","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1021\/jm4002988","article-title":"Interfacial Cavity Filling to Optimize CD4\u2013Mimetic Miniprotein Interactions with HIV-1 Surface Glycoprotein","volume":"56","author":"Acharya","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and Potent Neutralization of HIV-1 by a Gp41-Specific Human Antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1128\/JVI.00168-09","article-title":"Combinations of the First and Next Generations of Human Immunodeficiency Virus (HIV) Fusion Inhibitors Exhibit a Highly Potent Synergistic Effect against Enfuvirtide- Sensitive and -Resistant HIV Type 1 Strains","volume":"83","author":"Pan","year":"2009","journal-title":"J. Virol."},{"key":"ref_100","first-page":"1018","article-title":"Interactions between Different Generation HIV-1 Fusion Inhibitors and the Putative Mechanism Underlying the Synergistic Anti-HIV-1 Effect Resulting from Their Combination","volume":"26","author":"Cai","year":"2012","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"11126","DOI":"10.1074\/jbc.M800200200","article-title":"Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor","volume":"283","author":"He","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","article-title":"Efficacy and Safety of the Long-Acting Fusion Inhibitor Albuvirtide in Antiretroviral-Experienced Adults with Human Immunodeficiency Virus-1: Interim Analysis of the Randomized, Controlled, Phase 3, Non-Inferiority TALENT Study","volume":"133","author":"Su","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Chong, H., Yao, X., Zhang, C., Cai, L., Cui, S., Wang, Y., and He, Y. (2012). Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032599"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2005.06.008","article-title":"Identification of N-Phenyl-N\u2032-(2,2,6,6-Tetramethyl-Piperidin-4-Yl)-Oxalamides as a New Class of HIV-1 Entry Inhibitors That Prevent Gp120 Binding to CD4","volume":"339","author":"Zhao","year":"2005","journal-title":"Virology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1021\/acs.jmedchem.5b00709","article-title":"Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity","volume":"58","author":"Curreli","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1021\/jm034082o","article-title":"Discovery of 4-Benzoyl-1-[(4-Methoxy-1H- Pyrrolo[2,3-b]Pyridin-3-Yl)Oxoacetyl]-2- (R)-Methylpiperazine (BMS-378806):\u2009 A Novel HIV-1 Attachment Inhibitor That Interferes with CD4-Gp120 Interactions","volume":"46","author":"Wang","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1128\/AAC.00759-10","article-title":"Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects","volume":"55","author":"Hanna","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1089\/08892220152741450","article-title":"A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on Gp41 of Human Immunodeficiency Virus Type 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eaal2200","DOI":"10.1126\/sciimmunol.aal2200","article-title":"Potent and Broad HIV-Neutralizing Antibodies in Memory B Cells and Plasma","volume":"2","author":"Williams","year":"2017","journal-title":"Sci. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1128\/AAC.48.9.3253-3259.2004","article-title":"Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment","volume":"48","author":"Menzo","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1128\/JVI.00373-15","article-title":"Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket","volume":"89","author":"Su","year":"2015","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"198215","DOI":"10.1016\/j.virusres.2020.198215","article-title":"HIV-1 Gp41 Genetic Diversity and Enfuvirtide Resistance-Associated Mutations among Enfuvirtide-Na\u00efve Patients in Southern China","volume":"292","author":"Chang","year":"2021","journal-title":"Virus Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e00110-19","DOI":"10.1128\/AAC.00110-19","article-title":"Ibalizumab, a Novel Monoclonal Antibody for the Management of Multidrug-Resistant HIV-1 Infection","volume":"63","author":"Beccari","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_115","unstructured":"Khanlou, H., Gathe, J., Schrader, S., Towner, W., Weinheimer, S., and Lewis, S. (2011, January 17\u201320). Safety, Efficacy, and Pharmacokinetics of Ibalizumab in Treatment-Experienced HIV-1 Infected Patients: A Phase 2b Study. Proceedings of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1128\/JVI.02237-10","article-title":"Loss of Asparagine-Linked Glycosylation Sites in Variable Region 5 of Human Immunodeficiency Virus Type 1 Envelope Is Associated with Resistance to CD4 Antibody Ibalizumab","volume":"85","author":"Toma","year":"2011","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.00761-05","article-title":"Synergistic in Vitro Antiretroviral Activity of a Humanized Monoclonal Anti-CD4 Antibody (TNX-355) and Enfuvirtide (T-20)","volume":"50","author":"Zhang","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1128\/JVI.01954-06","article-title":"Clade-Specific Differences between Human Immunodeficiency Virus Type 1 Clades B and C: Diversity and Correlations in C3-V4 Regions of Gp120","volume":"81","author":"Gnanakaran","year":"2007","journal-title":"J. Virol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"440","DOI":"10.7326\/0003-4819-134-6-200103200-00008","article-title":"Use of Genotypic Resistance Testing to Guide HIV Therapy: Clinical Impact and Cost-Effectiveness","volume":"134","author":"Weinstein","year":"2001","journal-title":"Ann. Intern. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.qai.0000148533.12329.96","article-title":"A Randomized Controlled Trial of the Value of Phenotypic Testing in Addition to Genotypic Testing for HIV Drug Resistance: Evaluation of Resistance Assays (ERA) Trial Investigators","volume":"38","author":"Dunn","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(98)12291-2","article-title":"Drug-Resistance Genotyping in HIV-1 Therapy: The VIRADAPT Randomised Controlled Trial","volume":"353","author":"Durant","year":"1999","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","article-title":"A Randomized Study of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing in Patients Failing Therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS","volume":"14","author":"Baxter","year":"2000","journal-title":"AIDS"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00002030-200202150-00008","article-title":"Usefulness of Monitoring HIV Drug Resistance and Adherence in Individuals Failing Highly Active Antiretroviral Therapy: A Randomized Study (ARGENTA)","volume":"16","author":"Cingolani","year":"2002","journal-title":"AIDS"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00002030-200203290-00008","article-title":"Phenotypic or Genotypic Resistance Testing for Choosing Antiretroviral Therapy after Treatment Failure: A Randomized Trial","volume":"16","author":"Meynard","year":"2002","journal-title":"AIDS"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/cid\/cix542","article-title":"Should We Be Testing for Baseline Integrase Resistance in Patients Newly Diagnosed with Human Immunodeficiency Virus?","volume":"65","author":"Koullias","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"Calvez","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_127","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents (2018). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV, NIH Office of AIDS Research Advisory Council (OARAC)."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.12688\/f1000research.23379.1","article-title":"Cost Analysis of Implementing HIV Drug Resistance Testing in Kenya: A Case Study of a Service Delivery Site at a Tertiary Level Hospital in Kenya","volume":"9","author":"Gachogo","year":"2020","journal-title":"F1000Research"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1473-3099(16)30118-9","article-title":"Affordable HIV Drug-Resistance Testing for Monitoring of Antiretroviral Therapy in Sub-Saharan Africa","volume":"16","author":"Inzaule","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_130","first-page":"104243","article-title":"Development of a New Comprehensive HIV-1 Genotypic Drug Resistance Assay for All Commercially Available Reverse Transcriptase, Protease and Integrase Inhibitors in Patients Infected with Group M HIV-1 Strains","volume":"81","author":"Chrysostomou","year":"2020","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Manyana, S., Gounder, L., Pillay, M., Manasa, J., Naidoo, K., and Chimukangara, B. (2021). HIV-1 Drug Resistance Genotyping in Resource Limited Settings: Current and Future Perspectives in Sequencing Technologies. Viruses, 13.","DOI":"10.3390\/v13061125"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1097\/00002030-199912240-00001","article-title":"Rapid Decline in Detectability of HIV-1 Drug Resistance Mutations after Stopping Therapy","volume":"13","author":"Devereux","year":"1999","journal-title":"AIDS"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/jama.2010.980","article-title":"AIDS Working Group of MSF, for the Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries","volume":"304","author":"Balkan","year":"2010","journal-title":"JAMA"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"17334","DOI":"10.7448\/IAS.15.2.17334","article-title":"HIV Treatment and Care in Resource-Constrained Environments: Challenges for the next Decade","volume":"15","author":"Aoussi","year":"2012","journal-title":"J. Int. AIDS Soc."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects with Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_136","unstructured":"Grinsztejn, B., Hughes, M., Ritz, J., Salata, R., Mugyenyi, P., Hogg, E., Wieclaw, L., Gross, R., Godfrey, C., and Kumarasamy, N. (2018, January 4\u20137). Results of ACTG A5288: A Strategy Study in RLS for 3rd-Line ART Candidates. Proceedings of the Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMoa035026","article-title":"Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America","volume":"348","author":"Lalezari","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for Previously Treated Patients with R5 HIV-1 Infection","volume":"359","author":"Gulick","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/319368","article-title":"Evaluation of Chronic Hepatitis B Virus (HBV) Infection in Coinfected Patients Receiving Lamivudine as a Component of Anti-Human Immunodeficiency Virus Regimens","volume":"32","author":"Hoff","year":"2001","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_141","unstructured":"(2023, May 13). Available online: https:\/\/www.hcvguidelines.org\/unique-populations\/hiv-hcv."},{"key":"ref_142","unstructured":"Benson, C.A., Brooks, J.T., Holmes, K.K., Kaplan, J.E., Masur, H., and Pau, A. (2009). Guidelines for Prevention and Treatment Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association\/Infectious Diseases Society of America, Centers for Disease Control and Prevention."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/09540120410001683402","article-title":"Predictors of Antiretroviral Adherence","volume":"16","author":"Murphy","year":"2004","journal-title":"AIDS Care"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1007\/s10461-017-1808-4","article-title":"The Impact of Substance Use on Adherence to Antiretroviral Therapy Among HIV-Infected Women in the United States","volume":"22","author":"Zhang","year":"2018","journal-title":"AIDS Behav."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1055329003261981","article-title":"Stigma: A Health Barrier for Women with HIV\/AIDS","volume":"15","author":"Carr","year":"2004","journal-title":"J. Assoc. Nurses AIDS Care JANAC"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10461-006-9106-6","article-title":"The Role of HIV Serostatus Disclosure in Antiretroviral Medication Adherence","volume":"10","author":"Stirratt","year":"2006","journal-title":"AIDS Behav."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/108729103771928690","article-title":"Psychiatric and Social Barriers to HIV Medication Adherence in a Triply Diagnosed Methadone Population","volume":"17","author":"Palmer","year":"2003","journal-title":"AIDS Patient Care STDs"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-156-11-201206050-00419","article-title":"Guidelines for Improving Entry into and Retention in Care and Antiretroviral Adherence for Persons with HIV: Evidence-Based Recommendations from an International Association of Physicians in AIDS Care Panel","volume":"156","author":"Thompson","year":"2012","journal-title":"Ann. Intern. Med."},{"key":"ref_149","unstructured":"(2023, May 16). Available online: https:\/\/www.hiv-druginteractions.org\/checker."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/jcph.210","article-title":"Effect of Food on Rilpivirine\/Emtricitabine\/Tenofovir Disoproxil Fumarate, an Antiretroviral Single-Tablet Regimen for the Treatment of HIV Infection","volume":"54","author":"Custodio","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/0091270006298603","article-title":"The Effect of Different Meal Types on the Pharmacokinetics of Darunavir (TMC114)\/Ritonavir in HIV-Negative Healthy Volunteers","volume":"47","author":"Sekar","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.2169\/internalmedicine.48.1906","article-title":"Successful Absorption of Antiretroviral Drugs after Gastrojejunal Bypass Surgery Following Failure of Therapy through a Jejunal Tube","volume":"48","author":"Kamimura","year":"2009","journal-title":"Intern. Med. Tokyo Jpn."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/01.qai.0000245887.58886.ac","article-title":"Sustained Benefit from a Long-Term Antiretroviral Adherence Intervention. Results of a Large Randomized Clinical Trial","volume":"43","author":"Mannheimer","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_154","first-page":"127","article-title":"Investigational Antiretroviral Drugs: What Is Coming Down the Pipeline","volume":"25","author":"Gulick","year":"2018","journal-title":"Top. Antivir. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/COH.0000000000000469","article-title":"Fostemsavir: A New CD4 Attachment Inhibitor","volume":"13","author":"Cahn","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e740","DOI":"10.1016\/S2352-3018(20)30240-X","article-title":"Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals: Week 96 Results of the Phase 3 BRIGHTE Study","volume":"7","author":"Lataillade","year":"2020","journal-title":"Lancet HIV"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/QAD.0000000000002851","article-title":"Long-Term Efficacy and Safety of Fostemsavir among Subgroups of Heavily Treatment-Experienced Adults with HIV-1","volume":"35","author":"Ackerman","year":"2021","journal-title":"AIDS Lond. Engl."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Chang, X.L., Reed, J.S., Webb, G.M., Wu, H.L., Le, J., Bateman, K.B., Greene, J.M., Pessoa, C., Waytashek, C., and Weber, W.C. (2022). Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010396"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"106064","DOI":"10.1016\/j.phrs.2022.106064","article-title":"Leronlimab (PRO 140) in Vitro Activity against 4-Class Drug Resistant HIV-1 from Heavily Treatment Experienced Subjects","volume":"176","author":"Rusconi","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1802264","article-title":"Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption","volume":"380","author":"Wang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COH.0000000000000600","article-title":"Broadly Neutralizing Antibodies for the Treatment and Prevention of HIV Infection","volume":"15","author":"Caskey","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination Therapy with Anti-HIV-1 Antibodies Maintains Viral Suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","article-title":"Enhanced Neonatal Fc Receptor Function Improves Protection against Primate SHIV Infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals","volume":"24","author":"Gruell","year":"2018","journal-title":"Nat. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural Basis of HIV Inhibition by Translocation-Defective RT Inhibitor 4\u2032-Ethynyl-2-Fluoro-2\u2032-Deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_166","unstructured":"(2023, May 22). Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05052996."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/COH.0000000000000713","article-title":"Lenacapavir: A First-in-Class HIV-1 Capsid Inhibitor","volume":"17","author":"Shaik","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/jac\/dkab503","article-title":"Phenotypic Resistance to Lenacapavir and Monotherapy Efficacy in a Proof-of-Concept Clinical Study","volume":"77","author":"Margot","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciz938","article-title":"A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-Generation Maturation Inhibitor, in Participants with Human Immunodeficiency Virus Type 1 Infection","volume":"71","author":"DeJesus","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e00671","DOI":"10.1002\/prp2.671","article-title":"Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a next-Generation HIV-1 Maturation Inhibitor","volume":"8","author":"Joshi","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/cid\/ciab1065","article-title":"Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254","volume":"75","author":"Spinner","year":"2022","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults with HIV-1 Infection (ATLAS-2M), 48-Week Results: A Randomised, Multicentre, Open-Label, Phase 3b, Non-Inferiority Study","volume":"396","author":"Overton","year":"2020","journal-title":"Lancet"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/S0140-6736(20)32231-5","article-title":"Is It Time for Injectable Antiretroviral Therapy for HIV?","volume":"396","author":"Hoy","year":"2020","journal-title":"Lancet"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/COH.0000000000000158","article-title":"Implementation Challenges for Long-Acting Antivirals as Treatment","volume":"10","author":"Havlir","year":"2015","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2352-3018(19)30137-7","article-title":"Use of Electronic Health Record Data and Machine Learning to Identify Candidates for HIV Pre-Exposure Prophylaxis: A Modelling Study","volume":"6","author":"Marcus","year":"2019","journal-title":"Lancet HIV"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"100203","DOI":"10.1016\/j.eclinm.2019.10.016","article-title":"Algorithmic Prediction of HIV Status Using Nation-Wide Electronic Registry Data","volume":"17","author":"Ronit","year":"2019","journal-title":"EClinicalMedicine"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1089\/apc.2019.0056","article-title":"Using HIV Risk Prediction Tools to Identify Candidates for Pre-Exposure Prophylaxis: Perspectives from Patients and Primary Care Providers","volume":"33","author":"Gilkey","year":"2019","journal-title":"AIDS Patient Care STDs"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2147\/IJGM.S397031","article-title":"Artificial Intelligence and Machine Learning Based Prediction of Viral Load and CD4 Status of People Living with HIV (PLWH) on Anti-Retroviral Treatment in Gedeo Zone Public Hospitals","volume":"16","author":"Seboka","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/jcc.27061","article-title":"The Design of Compounds with Desirable Properties\u2013The Anti-HIV Case Study","volume":"44","author":"Novak","year":"2023","journal-title":"J. Comput. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Sarkar, C., Das, B., Rawat, V.S., Wahlang, J.B., Nongpiur, A., Tiewsoh, I., Lyngdoh, N.M., Das, D., Bidarolli, M., and Sony, H.T. (2023). Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032026"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10876-016-1100-1","article-title":"Mangrove-Mediated Green Synthesis of Silver Nanoparticles with High HIV-1 Reverse Transcriptase Inhibitory Potential","volume":"28","author":"Kumar","year":"2017","journal-title":"J. Clust. Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"100592","DOI":"10.1016\/j.hermed.2022.100592","article-title":"The Anti-HIV Activity of Biogenic Silver Nanoparticles Synthesized from Centella Asiatica Extracts","volume":"35","author":"Maduray","year":"2022","journal-title":"J. Herb. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s42269-022-00824-x","article-title":"Biosynthesis and Optimization of Highly Stable Gold Nanoparticles, Nanoconjugates, Nanodrug Conjugates and Chitosan Nanoconjugates Using Medicinal Plants","volume":"46","author":"Priya","year":"2022","journal-title":"Bull. Natl. Res. Cent."},{"key":"ref_185","first-page":"1","article-title":"Green Biosynthesis of Silver Nanoparticles (AgNPs) from Vitex Negundo Plant Extract and its Phytochemical Screening and Antimicrobial Assessment Next to Pathogenic Microbes","volume":"12","author":"Dogra","year":"2023","journal-title":"J. Microbiol. Biotechnol. Food Sci."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"102336","DOI":"10.1016\/j.eti.2022.102336","article-title":"Green Synthesis of Nanoparticles: Current Developments and Limitations","volume":"26","author":"Ying","year":"2022","journal-title":"Environ. Technol. Innov."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Parveen, K., Banse, V., and Ledwani, L. (2016). Green Synthesis of Nanoparticles: Their Advantages and Disadvantages, AIP Publishing LLC.","DOI":"10.1063\/1.4945168"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1732\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:32:47Z","timestamp":1760128367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/8\/1732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,13]]},"references-count":187,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["v15081732"],"URL":"https:\/\/doi.org\/10.3390\/v15081732","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,13]]}}}